【摘要】 目的探讨胸腺肽联合促肝细胞生长素治疗干扰素无效的慢性乙型病毒性肝炎的临床疗效。方法将干扰素治疗无效的98例慢性乙型病毒性肝炎患者随机分成3组,促肝细胞生长素组、胸腺肽组及联合治疗组,观察3组治疗3个月前后血清HbeAg/抗-Hbe转换率、血清HBV-DNA的阴转率及治疗结束6个月后随访半年的HBV-DNA的阳转率。结果治疗3个月后联合组的血清HbeAg/抗-Hbe转换率、HBV-DNA的阴转率均高于促肝细胞生长素,胸腺肽组。随访6个月,3组血清HBV-DNA的阳转反跳率,谷丙转氨酶与总胆红素复常率比较差异有统计学意义。结论胸腺肽联合促肝细胞生长素对干扰素治疗无效的慢性病毒性乙型肝炎效果较好,值得临床应用。更多还原

【Abstract】 Objective To investigate the curative effect of thymosin combined with hepatocyte growth-promoting factors to interferon refractory chronic viral hepatitis B.Methods 98 cases of interferon refractory chronic viral hepatitis B were randomly divided into three groups as hepatocyte growth factor group,thymopeptide group and combined therapy group,to observe the three groups about serum HbeAg/anti-Hbe conversion rate,serum HBV-DNA negative conversion rate before and after 3 months of treatment,and follow-up half year after six months of treatment to observe the HBV-DNA positive rate.Results Three months after the treatment,serum HbeAg /anti-Hbe conversion rate of combined therapy group and HBV-DNA negative conversion rate was higher than that of hepatocyte growth factor group,thymopeptide group,respectively.Follow-up of 6 months,the comparison of seroconversion bounce-back rate,the recovery rate of glutamate-pyruvate transaminase and bilirubin total in three groups had statistical significance.Conclusion Thymosin combined with hepatocyte growth-promoting factors to treat the chronic hepatitis B had better effect to interferon refractory chronic viral hepatitis B.And may be worth of clinical application.更多还原